SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $68
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $66 to $68.
BridgeBio Pharma’s Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US
The FDA has granted Fast Track Designation to BridgeBio Pharma Inc’s (NASDAQ:BBIO) BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type…
BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Therapy For The Treatment Of Limb-girdle Muscular Dystrophy Type 2i
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic
B of A Securities Upgrades BridgeBio Pharma to Buy, Announces $75 Price Target
B of A Securities analyst Geoff Meacham upgrades BridgeBio Pharma (NASDAQ:BBIO) from Neutral to Buy and announces $75 price target.
Unusual Options Activity Insight: BridgeBio Pharma
BridgeBio Pharma (NASDAQ:BBIO) shares experienced unusual options activity on Tuesday. The stock price moved down to $52.52 following the option alert.
SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $66
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers the price target from $71 to $66.
BridgeBio Pharma Q2 EPS $(0.66) Up From $(1.03) YoY
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.66) per share. This is a 35.92 percent increase over losses of $(1.03) per share from the same period last year.
BridgeBio Pharma Announces Collaborations With Three Academic Research Institutions
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic
BridgeBio Pharma Announces Collaborations With Three Academic Research Institutions
BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic